By Melinda Pautsch, Chief Commercial Officer, QuartzBio  I just returned from SCOPE 2026 with a familiar feeling—and a sharper sense of urgency. The conversations around biomarkers, biospecimens, and clinical operations weren’t about “doing things better” at the margins. They were about whether our operational foundations can keep up with what science—and regulators—are demanding. Across sessions […]